Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Aggregate statistics from Disclosed's verified COA corpus. All numbers are computed directly from lab-uploaded Certificates of Analysis — no editorial claims, no estimates.
COAs
306
Labs
15
2 verified
Vendors tested
52
Avg purity
99.7%
±1.4%
Endotoxin tested
35%
of all COAs tested
Sterility tested
14%
of all COAs tested
Methodology:Purity averages exclude values outside [50%, 100%] to filter unit misreads. "Vendors tested" counts distinct vendor IDs across all in-scope, non-withdrawn, extracted COAs. Endotoxin/sterility coverage denominators are all in-scope COAs (not filtered to parenteral form).
Data updates hourly. All figures are computed from lab-uploaded COAs; Disclosed does not perform independent testing.
Based on 306 Certificates of Analysis in the Disclosed corpus, Tirzepatide has an average HPLC purity of 99.7% (±1.4% std dev). This figure spans 52 vendors tested across 15 independent labs. Purity is measured by high-performance liquid chromatography (HPLC); values outside 50–100% are excluded as unit misreads.
15 distinct testing labs have produced COAs for Tirzepatide in the Disclosed database, covering 306 total tests across 52 vendors. 2 of those labs have a verified Disclosed partner account, meaning their COAs are uploaded directly by the lab.
35% of Tirzepatide COAs in the Disclosed corpus include endotoxin test results (USP <85>), and 14% include sterility results (USP <71>). Endotoxin and sterility testing matter for injectable-grade peptides — their absence in a COA does not indicate failure, but absence is common in HPLC-only testing workflows.
Verified labs with COAs for Tirzepatide in the Disclosed corpus include: ILS Labs (grade B, 14 COAs); Ethos Analytics (grade C, 2 COAs). These grades reflect Disclosed's credibility scoring of each lab's full COA corpus — purity distribution, safety panel breadth, and verification engagement.